Product
Entresto
Aliases
Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
6 clinical trials
5 indications
Indication
Bioequivalence StudyIndication
Chronic Heart FailureIndication
Healthy Control ParticipantsIndication
HypertensionIndication
Hypertensive heart diseaseClinical trial
A Bioequivalence Study of Two Formulations of Sacubitril/Valsartan 49 mg/51 mg Film-coated Tablets in Healthy Thai Subjects Under Fasting ConditionsStatus: Not yet recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Bioequivalence Study of Two Formulations of Sacubitril/Valsartan 97 mg/103 mg Film-coated Tablets in Healthy Thai Subjects Under Fasting ConditionsStatus: Not yet recruiting, Estimated PCD: 2024-04-01
Clinical trial
Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401)Status: Completed, Estimated PCD: 2023-04-21
Clinical trial
A Bioequivalence Study of Two Formulations of Sacubitril/Valsartan 24 mg/26 mg Film-coated Tablets in Healthy Thai Subjects Under Fasting ConditionsStatus: Not yet recruiting, Estimated PCD: 2024-03-01
Clinical trial
Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHTStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Role of ARNi in Ventricular Remodeling in Hypertensive LVHStatus: Recruiting, Estimated PCD: 2023-12-01